Skip to main content
SpringerLink
Log in

Screening for Ovarian Cancer

  • Chapter
  • First Online:
Preventive Oncology for the Gynecologist

  • 494 Accesses

Abstract

Gynecologic cancer is a major disease burden worldwide. Based on the 2012 GLOBOCAN Worldwide estimates of cancer incidences and mortality from the International Agency for Research on Cancer (IARC), cervical, endometrial, and ovarian cancers rank fourth, sixth, and seventh highest new cases, respectively, with cervical cancer and ovarian cancer as fourth and eighth leading cause of cancer deaths. From the 2014 Surveillance, Epidemiology, and End Results (SEER) Program data and the Centers for Disease Control and Prevention’s (CDC’s) National Program of Cancer Registries (NPCR) data in the United States, cancer of the uterine corpus was the fourth most common new cancer cases, with 52,630 new cases, and ovarian cancer was the fifth most common cause of death, with 14,270 deaths. The lifetime risk of a woman to develop ovarian cancer is 1 in 75 and the risk of death from the disease is 1 in 100. This chapter will discuss screening for ovarian cancer, which will be divided into screening among healthy individuals (general population and high-risk population) and individuals (asymptomatic or symptomatic) who have ovarian masses requiring differentiation of benign from malignant tumor.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.

    Article  PubMed  Google Scholar 

  2. Jiang X, Tang H. Epidemiology of gynecologic cancers in China. J Gynecol Oncol. 2018;29(1):e7.

    Article  PubMed  Google Scholar 

  3. Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a review. Cancer Biol Med. 2017;14(1):9–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Pal T, Permuth-Wey J, Betts JA, Krischer JP, Fiorica J, Arango H, et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer. 2005;104(12):2807–16.

    Article  CAS  PubMed  Google Scholar 

  5. Viswanathan A, Kim DH, Reid N, Kline DG. Surgical management of the pelvic plexus and lower abdominal nerves. Neurosurgery. 2009;65(4 Suppl):A44–51.

    Article  PubMed  Google Scholar 

  6. Huncharek M, Kupelnick B. Dietary fat intake and risk of epithelial ovarian cancer: a meta-analysis of 6,689 subjects from 8 observational studies. Nutr Cancer. 2001;40(2):87–91.

    Article  CAS  PubMed  Google Scholar 

  7. Crew KD, Neugut AI. Aspirin and NSAIDs: effects in breast and ovarian cancers. Curr Opin Obstet Gynecol. 2006;18(1):71–5.

    Article  PubMed  Google Scholar 

  8. Kjaer SK, Mellemkjaer L, Brinton LA, Johansen C, Gridley G, Olsen JH. Tubal sterilization and risk of ovarian, endometrial and cervical cancer. A Danish population-based follow-up study of more than 65 000 sterilized women. Int J Epidemiol. 2004;33(3):596–602.

    Article  PubMed  Google Scholar 

  9. Koshiyama M, Matsumura N. Recent concepts of ovarian carcinogenesis: type I and type II. Biomed Res Int. 2014;2014:934261.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Buys SS, Partridge E, Greene MH, Prorok PC, Reding D, Riley TL, et al. Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial. Am J Obstet Gynecol. 2005;193(5):1630–9.

    Article  PubMed  Google Scholar 

  11. Buys SS, Partridge E, Black A, Johnson CC, Lamerato L, Isaacs C, et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening randomized controlled trial. JAMA. 2011;305(22):2295–303.

    Article  CAS  PubMed  Google Scholar 

  12. Pinsky PF, Prorok PC, Yu K, Kramer BS, Black A, Gohagan JK, et al. Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years. Cancer. 2017;123(4):592–9.

    Article  PubMed  Google Scholar 

  13. Moyer VA. Screening for ovarian cancer: U.S. Preventive Services Task Force reaffirmation recommendation statement. Ann Intern Med. 2012;157(12):900–4.

    Article  PubMed  Google Scholar 

  14. Jacobs IJ, Menon U, Ryan A, Gentry-Maharaj A, Burnell M, Kalsi JK, et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet. 2016;387(10022):945–56.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Mills K, Fuh K. Recent advances in understanding, diagnosing, and treating ovarian cancer. F1000Res. 2017;6:84.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Daly M, Allen J, Axilbund J, Buys S, Crawford B, Farrell C, et al. NCCN clinical practice guidelines in oncology: genetic/familial high-risk assessment: breast and ovarian (version 1/2011). Fort Washington: National Comprehensive Cancer Network; 2011.

    Google Scholar 

  17. Skates SJ, Greene MH, Buys SS, Mai PL, Brown P, Piedmonte M, et al. Early detection of ovarian cancer using the risk of ovarian cancer algorithm with frequent CA125 testing in women at increased familial risk - combined results from two screening trials. Clin Cancer Res. 2017;23(14):3628–37.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst. 2009;101(2):80–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Kauff ND, Domchek SM, Friebel TM, Robson ME, Lee J, Garber JE, et al. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol. 2008;26(8):1331–7.

    Article  PubMed  Google Scholar 

  20. Mourits MJ, de Bock GH. European/U.S. comparison and contrasts in ovarian cancer screening and prevention in a high-risk population. Am Soc Clin Oncol Educ Book. 2017;37:124–7.

    Article  PubMed  Google Scholar 

  21. Ebell MH, Culp MB, Radke TJ. A systematic review of symptoms for the diagnosis of ovarian cancer. Am J Prev Med. 2016;50(3):384–94.

    Article  PubMed  Google Scholar 

  22. Ebell MH, Culp M, Lastinger K, Dasigi T. A systematic review of the bimanual examination as a test for ovarian cancer. Am J Prev Med. 2015;48(3):350–6.

    Article  PubMed  Google Scholar 

  23. Manegold-Brauer G, Bellin AK, Tercanli S, Lapaire O, Heinzelmann-Schwarz V. The special role of ultrasound for screening, staging and surveillance of malignant ovarian tumors: distinction from other methods of diagnostic imaging. Arch Gynecol Obstet. 2014;289(3):491–8.

    Article  CAS  PubMed  Google Scholar 

  24. Kaloo PL, Khazali S, Hoy D, Sadoon S. Management of suspected ovarian masses in premenopausal women. 2011.

    Google Scholar 

  25. American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins—Gynecology. Practice Bulletin No. 174: evaluation and management of adnexal masses. Obstet Gynecol. 2016;128(5):e210–e26.

    Article  Google Scholar 

  26. Timmerman D, Testa AC, Bourne T, Ferrazzi E, Ameye L, Konstantinovic ML, et al. Logistic regression model to distinguish between the benign and malignant adnexal mass before surgery: a multicenter study by the International Ovarian Tumor Analysis Group. J Clin Oncol. 2005;23(34):8794–801.

    Article  PubMed  Google Scholar 

  27. Timmerman D, Van Calster B, Testa A, Savelli L, Fischerova D, Froyman W, et al. Predicting the risk of malignancy in adnexal masses based on the simple rules from the International Ovarian Tumor Analysis group. Am J Obstet Gynecol. 2016;214(4):424–37.

    Article  PubMed  Google Scholar 

  28. Perkins GL, Slater ED, Sanders GK, Prichard JG. Serum tumor markers. Am Fam Physician. 2003;68(6):1075–82.

    PubMed  Google Scholar 

  29. Escudero JM, Auge JM, Filella X, Torne A, Pahisa J, Molina R. Comparison of serum human epididymis protein 4 with cancer antigen 125 as a tumor marker in patients with malignant and nonmalignant diseases. Clin Chem. 2011;57(11):1534–44.

    Article  CAS  PubMed  Google Scholar 

  30. Park Y, Lee JH, Hong DJ, Lee EY, Kim HS. Diagnostic performances of HE4 and CA125 for the detection of ovarian cancer from patients with various gynecologic and non-gynecologic diseases. Clin Biochem. 2011;44(10–11):884–8.

    Article  CAS  PubMed  Google Scholar 

  31. Sandri MT, Bottari F, Franchi D, Boveri S, Candiani M, Ronzoni S, et al. Comparison of HE4, CA125 and ROMA algorithm in women with a pelvic mass: correlation with pathological outcome. Gynecol Oncol. 2013;128(2):233–8.

    Article  CAS  PubMed  Google Scholar 

  32. Anton C, Carvalho FM, Oliveira EI, Maciel GA, Baracat EC, Carvalho JP. A comparison of CA125, HE4, risk ovarian malignancy algorithm (ROMA), and risk malignancy index (RMI) for the classification of ovarian masses. Clinics (Sao Paulo). 2012;67(5):437–41.

    Article  Google Scholar 

  33. Bristow RE, Hodeib M, Smith A, Chan DW, Zhang Z, Fung ET, et al. Impact of a multivariate index assay on referral patterns for surgical management of an adnexal mass. Am J Obstet Gynecol. 2013;209(6):581.e1–8.

    Article  Google Scholar 

  34. Zhang P, Wang C, Cheng L, Zhang P, Guo L, Liu W, et al. Development of a multi-marker model combining HE4, CA125, progesterone, and estradiol for distinguishing benign from malignant pelvic masses in postmenopausal women. Tumour Biol. 2016;37(2):2183–91.

    Article  CAS  PubMed  Google Scholar 

  35. Ueland FR. A perspective on ovarian cancer biomarkers: past, present and yet-to-come. Diagnostics (Basel). 2017;7(1):E14.

    Article  Google Scholar 

  36. Coleman RL, Herzog TJ, Chan DW, Munroe DG, Pappas TC, Smith A, et al. Validation of a second-generation multivariate index assay for malignancy risk of adnexal masses. Am J Obstet Gynecol. 2016;215(1):82.e1–e11.

    Article  Google Scholar 

  37. Bristow RE, Smith A, Zhang Z, Chan DW, Crutcher G, Fung ET, et al. Ovarian malignancy risk stratification of the adnexal mass using a multivariate index assay. Gynecol Oncol. 2013;128(2):252–9.

    Article  PubMed  Google Scholar 

  38. Ratnavelu ND, Brown AP, Mallett S, Scholten RJ, Patel A, Founta C, et al. Intraoperative frozen section analysis for the diagnosis of early stage ovarian cancer in suspicious pelvic masses. Cochrane Database Syst Rev. 2016;3:Cd010360.

    PubMed  Google Scholar 

  39. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Section of Gynecologic Oncology, De La Salle Health Sciences Institute, De La Salle University Medical Center, Dasmarnas City, Philippines

    Angelito Magno

Authors
  1. Angelito Magno
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Obstetrics and Gynecology, Babu Jagjivan Ram Memorial Hospital, New Delhi, India

    Sumita Mehta

  2. Department of Obstetrics and Gynecology, University College of Medical Sciences and Guru Teg Bahadur Hospital, New Delhi, India

    Anshuja Singla

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Magno, A. (2019). Screening for Ovarian Cancer. In: Mehta, S., Singla, A. (eds) Preventive Oncology for the Gynecologist. Springer, Singapore. https://doi.org/10.1007/978-981-13-3438-2_19

Download citation

  • DOI: https://doi.org/10.1007/978-981-13-3438-2_19

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-13-3437-5

  • Online ISBN: 978-981-13-3438-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation